The CoroNAb consortium comprises researchers from:
Karolinska Institutet (Sweden)
Statens Serum Institut (Denmark)
ETH Zurich (Switzerland)
Imperial College London (The United Kingdom)
CoroNAb is engaged in research aiming to understand SARS-CoV-2 and COVID-19.
CoroNAb is supported by funding from the European Union's Horizon 2020 Research and Innovation Programme, under grant agreement No. 101003653.
To investigate protein subunit immunization strategies that elicit antibodies that neutralize SARS-CoV-2.
To identify and study, in detail, the antibodies that are elicited by such immunization strategies.
To identify and characterize alpaca single-domain antibodies that can bind to and neutralize SARS-CoV-2.
To investigate new technologies for antibody optimization.
To model pandemic dynamics and the potential effects of interventions.